230 related articles for article (PubMed ID: 16681715)
1. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
[TBL] [Abstract][Full Text] [Related]
2. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study.
Bloss JD; Brady MF; Liao SY; Rocereto T; Partridge EE; Clarke-Pearson DL;
Gynecol Oncol; 2003 Apr; 89(1):148-54. PubMed ID: 12694669
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].
Gao YN; Liu JX; Wang W; Li WF; Tang WS
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):171-3. PubMed ID: 15946570
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of clinical characteristics of extraovarian peritoneal serous papillary carcinoma with papillary serous ovarian carcinoma].
Peng YZ; Shen K; Wu M; Huang HF; Pan LY; Yang JX; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):243-5. PubMed ID: 15924670
[TBL] [Abstract][Full Text] [Related]
5. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.
Bloss JD; Liao SY; Buller RE; Manetta A; Berman ML; McMeekin S; Bloss LP; DiSaia PJ
Gynecol Oncol; 1993 Sep; 50(3):347-51. PubMed ID: 8406199
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures.
Tentes AA; Mirelis CG; Markakidis SK; Bekiaridou KA; Bougioukas IG; Xanthoulis AI; Tsalkidou EG; Zafiropoulos GH; Nikas IH
Int J Gynecol Cancer; 2006; 16(2):490-5. PubMed ID: 16681716
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
Gao H; Yuan L; Han Y
World J Surg Oncol; 2016 Jun; 14(1):168. PubMed ID: 27341795
[TBL] [Abstract][Full Text] [Related]
10. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ
Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802
[TBL] [Abstract][Full Text] [Related]
11. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
12. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
13. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
14. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
15. Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
Saha A; Varughese M; Gallagher CJ; Orphanos G; Wilson P; Oram D; Jeyarajah A; Reynolds K; Shepherd J; McCormack M; Olaitan A; McDonald N; Mould T; McNeish I; Ledermann JA
Int J Gynecol Cancer; 2012 May; 22(4):566-72. PubMed ID: 22426404
[TBL] [Abstract][Full Text] [Related]
16. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
17. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
[TBL] [Abstract][Full Text] [Related]
18. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
[TBL] [Abstract][Full Text] [Related]
20. [Extraovarian peritoneal serous papillary carcinoma: an unusual surgical case].
Meier C; Seifert M; Wehrli H
Swiss Surg; 1999; 5(1):14-7. PubMed ID: 10073126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
